OREANDA-NEWS. RnR Market Research Offers Report by Research on Vietnam Pharmaceuticals and Healthcare Report Q3 2016.

BMI View: Leveraging Vietnam's National Expanded Immunisation Programme (EPI) will be of strategic benefit to multinational pharmaceutical firms with a strong vaccines portfolio. Government support for the initiative is expected to remain strong, which bodes well for firms as the EPI alleviates financial barriers that might dissuade patients from receiving treatment. A key risk to this approach stems from potential protectionist measures implemented by the Vietnamese government as it seeks to encourage the inclusion of locally produced vaccines.

Headline Expenditure Projections

- Pharmaceuticals: VND92.5trn (USD4.2bn) in 2015 to VND105.6trn (USD4.6bn) in 2016; +14.2% in local currency terms and +9.3% in US dollar terms. Forecast virtually unchanged from last quarter.

- Healthcare: VND304.3trn (USD13.9bn) in 2015 to VND333.4bn (USD14.6bn) in 2016; +9.6% in local currency terms and +4.9% in US dollar terms. Forecast increased compared to the previous quarter.